{
    "clinical_study": {
        "@rank": "114165", 
        "acronym": "RHYME", 
        "arm_group": {
            "arm_group_label": "Ranolazine", 
            "arm_group_type": "Experimental", 
            "description": "Ranolazine, 500 mg for 60 days"
        }, 
        "brief_summary": {
            "textblock": "The purpose of RHYME is to evaluate the safety and efficacy of ranolazine in Hypertrophic\n      Cardiomypathy patients with chest pain or dyspnea despite treatment with standard medical\n      therapy.  This is a small, pilot, open-label (non-randomized) study of an approved drug for\n      the treatment of angina in a novel patient population (adult patient population with\n      hypertrophic cardiomyopathy)."
        }, 
        "brief_title": "Ranolazine for the Treatment of Chest Pain in HCM Patients", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertrophic Cardiomyopathy", 
        "condition_browse": {
            "mesh_term": [
                "Cardiomyopathy, Hypertrophic", 
                "Hypertrophy", 
                "Cardiomyopathies"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 years or older\n\n          -  Left Ventricle wall thickness >/= 15mm in the absence of other condition causing\n             hypertrophy\n\n          -  Baseline Angina/Shortness of Breath Frequency of > 2 episodes per week\n\n          -  Willing to provide informed consent\n\n        Exclusion Criteria:\n\n          -  Severe stenotic valvular disease\n\n          -  Severe valvular regurgitation except mitral regurgitation due to systolic anterior\n             motion\n\n          -  Significant (>60% stenosis) coronary artery disease\n\n          -  Acute coronary syndrome within 30 days\n\n          -  Severe heart failure defined as LV systolic dysfunction with Ejection Fraction <40%\n             or NYHA class 4 symptoms\n\n          -  Severe renal impairment (glomerular filtration rate, <30 mL/min/1.73 m2)\n\n          -  Moderate-severe hepatic impairment (Child-Pugh classes B and C)\n\n          -  Hospitalization for cardiac reason within 3 months of enrollment\n\n          -  Anticipated changes to treatment of HCM within study period, including medications,\n             device implantation, or septal reduction therapies\n\n          -  Concomitant use of ketoconazole, macrolide antibiotics, and HIV protease inhibitors\n\n          -  Active myocarditis, pericarditis, or restrictive cardiomyopathy\n\n          -  Non-cardiac terminal illness with expected survival less than 6 months\n\n          -  Women who are of childbearing potential\n\n          -  Inability to perform or adhere to study protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01721967", 
            "org_study_id": "Pro00039302", 
            "secondary_id": "3938381"
        }, 
        "intervention": {
            "arm_group_label": "Ranolazine", 
            "intervention_name": "Ranolazine", 
            "intervention_type": "Drug", 
            "other_name": "Ranexa"
        }, 
        "intervention_browse": {
            "mesh_term": "Ranolazine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "chest pain", 
            "dyspnea"
        ], 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Following 2 months of therapy with ranolazine, symptomatic patients with Hypertrophic Cardiomyopathy will demonstrate signals of improvement on testing including angina frequency evaluation (number of episodes of angina per week).", 
            "measure": "Chest Pain", 
            "safety_issue": "No", 
            "time_frame": "60 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01721967"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Duke University", 
            "investigator_full_name": "Andrew Wang", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}